New Trial Pathways and Better Patient DataCo-hosted by IMI, EMA, NEWDIGS, and EFPIA “Overview the NEWDIGS Janus Initiative.” Mark Trusheim (MIT Sloan School of Management & MIT Center for Biomedical Innovation).

Keynote panel discussion: “Enterprising Breakthroughs and Catalyzing Collaboration in the Pursuit of Life-Transforming Rare Disease Treatments.”Gigi Hirsch (MIT).

Panel Discussion: “Future and Emerging Trends in Early Advice and Adaptive Licensing.”Gigi Hirsch (MIT).

Presentation: Adaptive Risk Management in Biotechnology: Applications to Transfats, Synthetic Biology and Pharmaceuticals.Ken Oye (MIT).

Co-sponsored by MIT Media Lab, Deloitte, & Decision Resources Group. The Future of Health Analytics. Panel Discussion on Emerging Trends, Technologies, & Opportunities, featuring Gigi Hirsch, MIT Center for BioMedical Innovation and Executive Director NEWDIGS, on the NEWDIGS Data Program.

Panel Discussion on Adaptive Licensing. James Anderson (GSK), Susanna Del-Signore (Sanofi), Hans-Georg Eichler (EMA), Gigi Hirsch (MIT)Full program here.

What is the current status of MAPPs in Europe and the US? FeaturingLuca Pani, Director General, Italian Medicines Agency Gigi Hirsch, Executive Director, CBI and Program Director, NEWDIGS, MIT, USA James Anderson, Head of Corporate Government Affairs, GlaxoSmithKline, UK Duane Schulthess, Managing Director, Vital Transformation (moderator) More information here.

Panel:  Early Access to Medicines:  What’s in it for Payers? Panelists:  Adam Heathfield (Pfizer), Mark Trusheim (MIT); Dan Ollendorf (ICER), Adrian Towse (Office of Health Economics, London).More information here.